Curation and interpretation of the most common biomarkers for common cancers, including review of clinical evidence, Tier level, drug sensitivity/resistance, prognosis.

Variant interpretation and reporting of NGS panel and Sanger sequencing tests for neurogenetic diseases.

Following the program for the certification by the American Board of Medical Genetics and Genomics (ABMGG) as Laboratory Clinical Molecular Geneticist, my training included:• Germline mutation analysis by Sanger sequencing, targeted exonic array and FDA approved eSensor assays,• Somatic mutation analysis by NGS panels of approximately 30 cancer patients during rotations in two labs,• Variant interpretation and curation following the new ACMG guidelines, • Development, validation and protocol composition of several sequencing tests and participation in the development of a NGS Metabolic panel, and • Experience with CAP regulations including policy and procedures review, composition of procedures, and assessment for CAP compliance. Rotations done during the fellowship: • Biochemical Genetics: Denver Genetics Biochemical Laboratory, CHCO • Cytogenetics: Colorado Genetics Laboratories • Leukemia, Lymphoma Genetics: Molecular Diagnostics Laboratory, CHCO • Solid Cancer Genetics: Colorado Molecular Correlates Laboratory, (CMOCO) • Genetic clinics: General Genetics, Metabolic, Cardiovascular, Skeletal dysplasia, Neurofibromatosis, Cleft, 22q, at CHCO; Adult Genetics at University of Colorado Hospital.

Continuing the research on Genetic predisposition for Alcoholism, I analyzed the contribution of variations in adenylyl cyclase genes to a personality trait, called behavioral disinhibition which is associated with increased risk for addiction.

Genome Wide Association Studies of Alcoholism and Depression.

I taught Biology courses for Biology majors and non-majors.

Generated transgenic mice.